Formation Bio: How AI Is Reshaping Drug Development Formation Bio, a New York City-based startup backed by prominent investors including Sam Altman, Andreessen Horowitz, and Sequoia Capital, is pioneering an AI-driven approach to accelerate drug development. The company focuses on streamlining clinical trials—the most time-consuming and costly phase of bringing new medicines to market—by applying artificial intelligence to improve efficiency across the development lifecycle. The company was co-founded by Benjamine Liu, who serves as CEO, and Linhao Zhang, the CTO. Liu’s background in computational biology, including neuroscience research at Oxford and the University of Pennsylvania, informed his belief that AI could solve critical bottlenecks in drug development. Zhang, a software developer previously at Salesforce and Oscar Insurance, brings technical expertise to build the company’s technology-forward platform. Formation Bio’s model centers on licensing drug candidates from biotech and pharmaceutical partners and advancing them through clinical development using AI-optimized processes. Rather than focusing on drug discovery, the company targets clinical development—a phase where up to 90% of drug candidates fail and which can take a decade and cost up to $5.5 billion per approved drug. By automating tasks such as patient recruitment, study startup, and adverse event reporting, Formation Bio aims to reduce delays and increase success rates. In June 2024, Formation Bio announced a $372 million Series D funding round led by Andreessen Horowitz, with participation from Sanofi, Sequoia Capital, Thrive Capital, Emerson Collective, and other investors. This round brought the company’s total funding to over $600 million, according to PitchBook. Although the company did not disclose its new valuation, a spokesperson described it as a “material step up” from its previous $1 billion Series C valuation. The company’s leadership emphasizes that combining deep expertise in both technology and pharmaceuticals is essential to transforming an industry long dominated by traditional approaches. Formation Bio positions itself as a builder of the “pharma company of the future,” aiming to deliver new treatments to patients faster and more efficiently by integrating AI into every stage of clinical development. As drug development costs continue to rise and timelines lengthen, Formation Bio’s AI-native strategy represents a growing trend of tech-driven innovation in healthcare. By addressing inefficiencies in clinical trials, the company seeks to increase the number of viable treatments that reach patients while lowering the financial and temporal barriers inherent in modern drug development.
17